<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327248</url>
  </required_header>
  <id_info>
    <org_study_id>FRA-BO</org_study_id>
    <nct_id>NCT01327248</nct_id>
  </id_info>
  <brief_title>Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans</brief_title>
  <acronym>Frabo</acronym>
  <official_title>Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this case-control study is the characterization of the bronchial and systemic&#xD;
      inflammation of children and young adults with bronchiolitis obliterans.&#xD;
&#xD;
      On the first visit subjects are asked to perform a lung function test (spirometry, body&#xD;
      plethysmography with helium). Further levels of eNO and eCO are determined. A blood sample is&#xD;
      drawn to describe the inflammatory status. Bronchial inflammation will be measured in induced&#xD;
      sputum. At the second visit, a non-specific bronchial provocation testing (PD20 FEV1&#xD;
      methacholine) is performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      The aim of this study is the characterization of patients with bronchiolitis obliterans in&#xD;
      terms of lung function, bronchial hyperreactivity and the degree of the systemic and&#xD;
      bronchial inflammation.&#xD;
&#xD;
      Sputum and serum samples are analyzed by quantitative real-time polymerase chain reaction&#xD;
      (PCR) (qRT-PCR) and by cytometric bead assay (CBA). Components of the innate immune system&#xD;
      (mannose-binding protein, TLR recognition proteins and surfactant proteins) are genetically&#xD;
      determined from sputum or blood respectively. In the conduct of this study the investigators&#xD;
      will retrospectively and systematically evaluate the available high-resolution computed&#xD;
      tomography (HRCT) studies of affected patients&#xD;
&#xD;
      Methods and Work Programme:&#xD;
&#xD;
      This study consists of two study visits (V1 and V2)&#xD;
&#xD;
      V1:&#xD;
&#xD;
        -  Measurement of nitric oxide in expired air (eNO)&#xD;
&#xD;
        -  Measurement of carbon monoxide in the exhaled air (eCO)&#xD;
&#xD;
        -  Lung function testing with spirometry and body plethysmography&#xD;
&#xD;
        -  Blood test: blood count, CRP, RAST, serum inflammatory mediators, genetic markers of the&#xD;
           non-specific pulmonary defense system&#xD;
&#xD;
        -  Induced sputum for inflammatory mediators and microbiological investigations&#xD;
&#xD;
      V2:&#xD;
&#xD;
      â€¢ Unspecific bronchial provocation test with methacholine (PD20 FEV1 methacholine)&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Children and young people (6 - 25 years of age). Both the patients and the healthy subjects&#xD;
      are recruited from the outpatient clinic of Pediatric Allergy and Pulmonology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Bronchiolitis Obliterans</condition>
  <arm_group>
    <arm_group_label>affected patients</arm_group_label>
    <description>20 Patients suffering from bronchiolitis obliterans</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-affected patients</arm_group_label>
    <description>20 matched controls not suffering from bronchiolitis obliterans</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, and Sputum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study is carried out in children and young adults (6 to 25 years). Both the patients&#xD;
        (20) and the healthy subjects (20) are recruited from the outpatient clinic of the&#xD;
        departement of Pediatric Allergy and Pulmonology, University Clinic, JW Goethe University,&#xD;
        Frankfurt/M, Germany.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  between 6 and 25 years of age&#xD;
&#xD;
          -  Known bronchiolitis obliterans / no bronchiolitis obliterans(depending on the study&#xD;
             group)&#xD;
&#xD;
          -  Ability to perform lung function tests and inhalation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;6 and &gt; 25 years of age on the day of written informed consent&#xD;
&#xD;
          -  Acute illness with systemic or bronchial inflammation&#xD;
&#xD;
          -  every chronic condition or infection (eg HIV, tuberculosis, malignancy)&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  known alcohol and/ or drug abuse&#xD;
&#xD;
          -  Inability to understand the extent and scope of the study&#xD;
&#xD;
          -  Participation in another study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Rosewich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital, Goethe-University</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kurland G, Michelson P. Bronchiolitis obliterans in children. Pediatr Pulmonol. 2005 Mar;39(3):193-208. Review.</citation>
    <PMID>15635614</PMID>
  </reference>
  <reference>
    <citation>Pichler M, Herrmann G, Schmidt H, Ahrens P, Zielen S. Persistent adenoviral infection and chronic obstructive bronchitis in children: is there a link? Pediatr Pulmonol. 2001 Nov;32(5):367-71.</citation>
    <PMID>11596161</PMID>
  </reference>
  <reference>
    <citation>Pichler MN, Reichenbach J, Schmidt H, Herrmann G, Zielen S. Severe adenovirus bronchiolitis in children. Acta Paediatr. 2000 Nov;89(11):1387-9.</citation>
    <PMID>11106056</PMID>
  </reference>
  <reference>
    <citation>Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003 Jul 1;168(1):121-5. Epub 2003 Apr 2.</citation>
    <PMID>12672648</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Dr. med. Martin Rosewich</investigator_full_name>
    <investigator_title>Martin Rosewich, MD</investigator_title>
  </responsible_party>
  <keyword>Bronchiolitis obliterans</keyword>
  <keyword>HRCT</keyword>
  <keyword>Sputum</keyword>
  <keyword>Blood</keyword>
  <keyword>Inflammation</keyword>
  <keyword>adaptive immune system</keyword>
  <keyword>innate immune system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

